Camrese Kit
Product Images NDC 0093-3134

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Camrese (NDC 0093-3134). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 1

A bar chart depicting the percentage of subjects experiencing bleeding and/or spotting versus bleeding alone across four treatment cycles of Camrese (Levonorgestrel / Ethinyl Estradiol and Ethinyl Estradiol). The x-axis displays cycles 1 to 4 with corresponding days and sample sizes, while the y-axis shows percent values up to 80%. Each cycle features paired bars indicating bleeding and/or spotting (higher bar) and bleeding alone (lower bar) for durations of ≥7 days and ≥20 days.*

FDA Label Image

Image 2

A forest plot displaying effect estimates with confidence intervals from multiple epidemiological studies comparing oral contraceptive use (Ever COC use vs Never use and Current COC use vs Never use). The horizontal axis represents effect estimates, with several studies listed on the vertical axis and their corresponding odds ratios, relative risks, and hazard ratios on the right.*

FDA Label Image

Image 3

Chemical structure of the active ingredient levonorgestrel, showing its molecular framework with key atoms and bonds as typically depicted in pharmaceutical labeling.*

FDA Label Image

Image 4

Chemical structure diagram of Ethinyl Estradiol, an active ingredient in the pharmaceutical KIT product Camrese by Teva Pharmaceuticals USA, Inc.*

FDA Label Image

Image 5

A vertical effectiveness chart illustrating pregnancy rates per 100 women in one year related to birth control methods. Higher effectiveness methods such as implants, injections, intrauterine devices, and sterilization are listed with fewer than 1 pregnancy per 100 women, while non-use of birth control corresponds to 85 or more pregnancies per 100 women. The chart categorizes methods by decreasing pregnancy rates, including birth control pills, skin patches, vaginal rings, condoms, diaphragms, abstinence during fertile days, spermicides, and withdrawal.*

FDA Label Image

Image 6

Blister packaging for Camrese oral contraceptive tablets, a kit containing levonorgestrel/ethinyl estradiol and ethinyl estradiol tablets. The image shows three rectangular gray blister cards numbered 2-4, 5-8, and 9-13, each with 28 circular tablets arranged in 4 rows and 7 columns labeled by days of the week (Sunday to Saturday). Each blister card includes the Camrese brand name and active ingredients with strengths (levonorgestrel/ethinyl estradiol 0.15 mg/0.03 mg and ethinyl estradiol 0.01 mg). The labeler is Teva Pharmaceuticals USA, Inc.*

FDA Label Image

Image 7

Camrese kit by Teva Pharmaceuticals USA, Inc., containing levonorgestrel and ethinyl estradiol tablets, 0.15 mg/0.03 mg, and ethinyl estradiol tablets, 0.01 mg. The packaging indicates 2 extended-cycle tablet dispensers with 91 tablets each and includes NDC 0093-3134-82. The label shows dosage instructions and storage information.*

FDA Label Image

Image 8

Box packaging label for Camrese oral contraceptive kit by Teva Pharmaceuticals USA, Inc. It contains 2 extended-cycle tablet dispensers with 91 tablets each. Active ingredients are levonorgestrel 0.15 mg, ethinyl estradiol 0.03 mg, and ethinyl estradiol 0.01 mg tablets. The label includes product name, dosage form, strength, NDC 0093-3134-82, and safety information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.